These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10555884)

  • 21. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Kaur L; Sharma S
    Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
    Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
    J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
    Lisbona MP; Maymo J; Perich J; Almirall M; Pérez-García C; Carbonell J
    J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality.
    Nikolaisen C; Figenschau Y; Nossent JC
    J Rheumatol; 2008 Mar; 35(3):380-6. PubMed ID: 18260177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study.
    Eggelmeijer F; Papapoulos SE; van Paassen HC; Dijkmans BA; Breedveld FC
    J Rheumatol; 1994 Nov; 21(11):2016-20. PubMed ID: 7869303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
    Tsuji S; Tomita T; Nakase T; Hamada M; Kawai H; Yoshikawa H
    Int J Rheum Dis; 2014 Jan; 17(1):44-9. PubMed ID: 24472266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of selected bone metabolism markers in rheumatoid arthritis patients.
    Matuszewska A; Szechiński J
    Adv Clin Exp Med; 2013; 22(2):193-202. PubMed ID: 23709375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review.
    Sakthiswary R; Das S
    Curr Drug Targets; 2013 Dec; 14(13):1552-7. PubMed ID: 23848441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients.
    Korczowska I; Lacki JK; Hrycaj P
    Yonsei Med J; 2013 Jan; 54(1):183-8. PubMed ID: 23225817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.
    Xie Z; Liu G; Tang P; Sun X; Chen S; Qin A; Zhu P; Zhang J; Fan S
    Drug Deliv; 2018 Nov; 25(1):187-197. PubMed ID: 29303005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rheumatoid arthritis and bone -periarticular and systemic bone loss-].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2013 Feb; 23(2):249-55. PubMed ID: 23354093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.